Anderson KN, et al. - Given the recommendation from the American Heart Association to provide contraceptive counseling to women with congenital heart defects (CHD) early in their reproductive years, researchers here reported recent female sterilization and reversible prescription contraceptive method use by presence of CHD and CHD severity in 2014. They assessed women aged 15 to 44 years with prescription drug coverage in 2014, who were enrolled ≥ 11 months annually in employer-sponsored health plans between 2011 and 2014, using IBM MarketScan Commercial Databases. Slight variation in recent sterilization or current reversible prescription contraceptive method use was observed among women with (39.2%) and without (37.3%) CHD, adjusted prevalence ratios (aPRs) = 1.04, 95% CI [1.01-1.07]. A higher likelihood of using any Tier I method was observed among women with CHD (12.9%) vs women without CHD (9.3%), aPR = 1.41, 95% CI [1.33-1.50]. Women with severe, vs non-severe, CHD showed less likelihood of using any method, aPR = 0.85, 95% CI [0.78-0.92], or Tier I method, aPR = 0.84, 95% CI [0.70-0.99]. The use of any included method was observed in nearly 60% of women with obstetrics-gynecology and < 40% with cardiology encounters. Findings suggest a possibility of the presence of missed opportunities for providers to increase uptake of safe, effective contraceptive methods for women with CHD who wish to avoid pregnancy.